Lantheus Holdings, Inc. Impairment of Real Estate
Lantheus Holdings, Inc. (LNTH) reported Impairment of Real Estate of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfRealEstate · last filed 2020-02-25
- Lantheus Holdings, Inc. impairment of real estate for fiscal 2019 was $0.00.
- Lantheus Holdings, Inc. impairment of real estate for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Lantheus Holdings, Inc. impairment of real estate for fiscal 2017 was $912.00K.
- Lantheus Holdings, Inc. impairment of real estate for fiscal 2016 was $0.00.
| Period end | Impairment of Real Estate 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2017-12-31 | $912.00K 10-K · filed 2020-02-25 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-20 |
| 2015-12-31 | $0.00 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |